GUARD THERAPEUTICS INTERNATIONAL AB Guard Therapeutics International AB Stock
Equities
GUARD
SE0021181559
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.8 SEK | 0.00% |
|
-6.88% | -16.76% |
| Sales 2023 | - | Sales 2024 * | - | Capitalization | 300M 3.27B |
|---|---|---|---|---|---|
| Net income 2023 | -113M -1.23B | Net income 2024 * | -99M -1.08B | EV / Sales 2023 | - |
| Net cash position 2023 * | 67M 731M | Net cash position 2024 * | 70M 763M | EV / Sales 2024 * | - |
| P/E ratio 2023 |
-3.18
x | P/E ratio 2024 * |
-3.03
x | Employees | 12 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 60.37% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -6.88% | ||
| Current month | +61.08% | ||
| 1 month | +65.56% | ||
| 3 months | +24.17% | ||
| 6 months | -6.88% | ||
| Current year | -16.76% |
1 week
27.00
31.80
1 month
16.6033.60
Current year
16.0037.90
1 year
5.1049.80
3 years
5.10112.50
5 years
5.10130.00
10 years
5.1013 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 18-11-30 | |
Karin Botha
DFI | Director of Finance/CFO | 51 | 20-09-13 |
Michael Reusch
CTO | Chief Tech/Sci/R&D Officer | 64 | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Johan Bygge
CHM | Chairman | 68 | 21-04-30 |
Göran Forsberg
BRD | Director/Board Member | 61 | 19-05-28 |
Fredrik Lehmann
BRD | Director/Board Member | 48 | 22-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 29.8 | 0.00% | 6 031 |
| 24-04-25 | 29.8 | -2.61% | 7,991 |
| 24-04-24 | 30.6 | +3.38% | 3,887 |
| 24-04-23 | 29.6 | +2.78% | 9,270 |
| 24-04-22 | 28.8 | -10.00% | 16,876 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 09:43 am EDT
More quotes
A1M Pharma AB is a Sweden-based company, which is active within the healthcare sector. The Company conducts development and commercialization of treatment and diagnostics based on the alpha-1-microglobulin (A1M) protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic uses, such as alleviation of autoimmune diseases and stroke treatment. The Company works with the protein and conducts research at the Biomedical Center in Lund University, Sweden. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries.
Calendar
2024-05-07
- Q1 2024 Earnings Release
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.76% | 27.49M | |
| +1.69% | 42.59B | |
| +7.51% | 40.65B | |
| +48.49% | 40.57B | |
| -11.96% | 26.77B | |
| +8.10% | 24.81B | |
| -24.70% | 18.17B | |
| +29.12% | 12.05B | |
| -2.82% | 11.7B | |
| +7.47% | 11.1B |
- Stock Market
- Equities
- GUARD Stock
